A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Phase of Trial: Phase IV
Latest Information Update: 05 May 2018
Price : $35 *
At a glance
- Drugs Corticotropin (Primary)
- Indications Membranous glomerulonephritis; Proteinuria
- Focus Therapeutic Use
- Acronyms CHART
- Sponsors Mallinckrodt Inc.; Questcor Pharmaceuticals
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.